132 related articles for article (PubMed ID: 24603434)
1. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome.
Roberts ME; Riegert-Johnson DL; Thomas BC; Rumilla KM; Thomas CS; Heckman MG; Purcell JU; Hanson NB; Leppig KA; Lim J; Cappel MA
Genet Med; 2014 Sep; 16(9):711-6. PubMed ID: 24603434
[TBL] [Abstract][Full Text] [Related]
2. Patients with a new-onset cutaneous sebaceous neoplasm following immunosuppression should be evaluated for Muir-Torre syndrome with germline mismatch repair gene mutation analysis: case reports.
Cohen PR; Kurzrock R
Dermatol Online J; 2024 Mar; 30(1):. PubMed ID: 38762859
[TBL] [Abstract][Full Text] [Related]
3. Sebaceomas in a Muir-Torre-like Phenotype in a Patient with MUTYH-Associated Polyposis.
Guarrera J; Prezzano JC; Mannava KA
Dermatopathology (Basel); 2024 Mar; 11(1):124-128. PubMed ID: 38534264
[TBL] [Abstract][Full Text] [Related]
4. Sebaceous Carcinoma Incidence and Survival Among Solid Organ Transplant Recipients in the United States, 1987-2017.
Sargen MR; Cahoon EK; Lynch CF; Tucker MA; Goldstein AM; Engels EA
JAMA Dermatol; 2020 Dec; 156(12):1307-1314. PubMed ID: 33146669
[TBL] [Abstract][Full Text] [Related]
5. Mosaic Muir Torre Syndrome: Keratoacanthoma as a Piece of the Puzzle.
O'Brien A; Macfarlane S; Sommerlad M; Schirwani S
Am J Dermatopathol; 2024 Mar; 46(3):162-166. PubMed ID: 38170727
[TBL] [Abstract][Full Text] [Related]
6. Sebaceous carcinoma in a 54-year-old Black African man after cancer chemotherapy: a case report.
Olaofe OO; Adewara BA; Okongwu CC; Abdullahi YO
J Med Case Rep; 2024 Mar; 18(1):159. PubMed ID: 38500211
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET-positive lower-extremity sebaceous-gland carcinoma in a patient with Muir-Torre syndrome.
Kviatkovsky B; Landau E; Siddique M; Hossri S; Ebaee A; Attalah JP; Picon A; Brenner A
Radiol Case Rep; 2015; 10(2):1115. PubMed ID: 27398125
[TBL] [Abstract][Full Text] [Related]
8. Sebaceous neoplasms: Just the thin end of the wedge.
Kyriakou A; Galanis N; Stavride E; Patsatsi A; Lazaridou E; Tsiridis E
Clin Case Rep; 2020 Feb; 8(2):393-395. PubMed ID: 32128198
[TBL] [Abstract][Full Text] [Related]
9. Unusual cystic sebaceous neoplasm prompts cascade testing.
Hotchkiss RA; Yang F; Gadarowski MB; Orejudos MP; Robinson CAH
JAAD Case Rep; 2024 May; 47():64-67. PubMed ID: 38655502
[No Abstract] [Full Text] [Related]
10. Atypical Periocular Lesions: Muir-Torre Syndrome.
Chau V; DeLuca N; Tan C; Fasih-Ahmad S; Dubovy SR; Rong AJ
Ophthalmic Plast Reconstr Surg; 2024 Apr; ():. PubMed ID: 38687295
[No Abstract] [Full Text] [Related]
11. Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm.
Everett JN; Raymond VM; Dandapani M; Marvin M; Kohlmann W; Chittenden A; Koeppe E; Gustafson SL; Else T; Fullen DR; Johnson TM; Syngal S; Gruber SB; Stoffel EM
JAMA Dermatol; 2014 Dec; 150(12):1315-21. PubMed ID: 25006859
[TBL] [Abstract][Full Text] [Related]
12. Muir-Torre syndrome (MTS): An update and approach to diagnosis and management.
John AM; Schwartz RA
J Am Acad Dermatol; 2016 Mar; 74(3):558-66. PubMed ID: 26892655
[TBL] [Abstract][Full Text] [Related]
13. Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases.
Boennelycke M; Thomsen BM; Holck S
Pathol Res Pract; 2015 Jan; 211(1):78-82. PubMed ID: 25457183
[TBL] [Abstract][Full Text] [Related]
14. Muir-Torre syndrome.
Bhaijee F; Brown AS
Arch Pathol Lab Med; 2014 Dec; 138(12):1685-9. PubMed ID: 25427047
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of universal immunohistochemical screening of sebaceous neoplasms in a service setting.
Schon K; Rytina E; Drummond J; Simmonds J; Abbs S; Sandford R; Tischkowitz M
Clin Exp Dermatol; 2018 Jun; 43(4):410-415. PubMed ID: 29333623
[TBL] [Abstract][Full Text] [Related]
16. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
17. A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients.
Snowsill T; Huxley N; Hoyle M; Jones-Hughes T; Coelho H; Cooper C; Frayling I; Hyde C
BMC Cancer; 2015 Apr; 15():313. PubMed ID: 25910169
[TBL] [Abstract][Full Text] [Related]
18. Defective DNA mismatch repair activity is common in sebaceous neoplasms, and may be an ineffective approach to screen for Lynch syndrome.
Lamba AR; Moore AY; Moore T; Rhees J; Arnold MA; Boland CR
Fam Cancer; 2015 Jun; 14(2):259-64. PubMed ID: 25637498
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
